Merck: FDA grants Breakthrough Therapy designation to sacituzumab tirumotecan
Merck (MRK) announced that the U.S. FDA has granted Breakthrough Therapy designation to sacituzumab tirumotecan for the treatment of patients with advanced or metastatic nonsquamous non-small cell ...
Cure Today14 小时
FDA Grants Breakthrough Therapy Designation to Sac-TMT for Some with NSCLC
The FDA has granted Breakthrough Therapy designation to sacituzumab tirumotecan for patients with advanced or metastatic ...
Merck Receives FDA Breakthrough Therapy Designation for Investigational Lung Cancer Treatment
Merck ( MRK, Financials) stated that sacituzumab tirumotecan (sac-TMT) was designated a Breakthrough Therapy by the FDA for advanced or metastatic nonsquamous non-small cell lung cancer with epidermal ...
MRK: Sac-TMT Gets FDA Breakthrough Therapy Designation For EGFR-mutated Advanced Or ...
Merck & Co., Inc. (MRK) announced Tuesday that the U.S. Food and Drug Administration has granted Breakthrough Therapy designation to ...